<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620811</url>
  </required_header>
  <id_info>
    <org_study_id>AK002-016X</org_study_id>
    <nct_id>NCT04620811</nct_id>
  </id_info>
  <brief_title>An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of&#xD;
      lirentelimab given monthly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of lirentelimab by evaluating adverse events assessed using the CTCAE version 5.0</measure>
    <time_frame>Day 561 (End of Study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of lirentelimab as assessed by symptom-directed physical examination of reported or observed patient symptoms warranting examination, including assessments of possible infusion site reactions and infusion-related reactions</measure>
    <time_frame>Day 1 to Day 561 (End of Study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of symptoms of EG and/or EGE using a daily disease-specific patient questionnaire (PRO Questionnaire)</measure>
    <time_frame>Basline to Day 561 (End of Study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the number of eosinophils in gastric and/or duodenal mucosa</measure>
    <time_frame>Baseline to Day 505</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Eosinophilic Gastritis</condition>
  <condition>Eosinophilic Duodenitis</condition>
  <arm_group>
    <arm_group_label>3.0 mg/kg of Lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive up to 18 monthly doses (3mg/kg) of lirentelimab (AK002)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lirentelimab</intervention_name>
    <description>Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8</description>
    <arm_group_label>3.0 mg/kg of Lirentelimab (AK002)</arm_group_label>
    <other_name>AK002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent.&#xD;
&#xD;
          2. Completed Study AK002-016, defined as having received 6 infusions of study drug and&#xD;
             followed through Day 176 (Â±3) or completed Study AK002-012, defined as having received&#xD;
             the cohort-appropriate amount of doses and followed for 5 months after last dose of&#xD;
             study drug.&#xD;
&#xD;
          3. If patient is on pre-existing dietary restrictions, willingness to maintain those&#xD;
             restrictions, throughout the study.&#xD;
&#xD;
          4. Able and willing to comply with all study procedures.&#xD;
&#xD;
          5. Female patients must be either post-menopausal for at least 1 year or surgically&#xD;
             sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 3&#xD;
             months, or if of childbearing potential, have a negative pregnancy test and agree to&#xD;
             use dual methods of contraception, or abstain from sexual activity until the end of&#xD;
             the study, or for 120 days following the last dose of study drug, whichever is longer.&#xD;
&#xD;
          6. Male patients with female partners of childbearing potential must agree to use a&#xD;
             highly effective method of contraception until the end of the study or for 120 days&#xD;
             following the last dose of study drug, whichever is longer. All fertile men with&#xD;
             female partners of childbearing potential should be instructed to contact the&#xD;
             Investigator immediately if they suspect their partner might be pregnant at any time&#xD;
             during study participation.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to any constituent of the study drug.&#xD;
&#xD;
          2. Any disease, condition (medical or surgical), or cardiac abnormality, which, in the&#xD;
             opinion of the Investigator, would place the patient at increased risk.&#xD;
&#xD;
          3. Planned or expected vaccination with live attenuated vaccines during the Treatment&#xD;
             Period, or vaccination expected within 5 half-lives (4 months) of AK002&#xD;
             administration.&#xD;
&#xD;
          4. Women who are pregnant, breastfeeding, or planning to become pregnant while&#xD;
             participating in the study.&#xD;
&#xD;
          5. Any other reason that, in the opinion of the Investigator or Medical Monitor, makes&#xD;
             the patient unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Rasmussen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Hixson</city>
        <state>Tennessee</state>
        <zip>37343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Duodenitis</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

